TFXHealthcare · Medical Instruments & SuppliesThe 12 Wall Street analysts covering Teleflex, Inc. hold a median 12-month price target of $155 — +11.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 26 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Teleflex, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (28): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (20): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on TFX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +11.5% from it.
Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Oct 2026 | Truist Securities | Maintains | Hold | $150 → $142 |
| 28 Sept 2026 | B of A Securities | Upgrade | Buy | $145 → $158 |
| 28 Sept 2026 | B of A Securities | Upgrade | Buy | — |
| 25 Aug 2026 | Needham | Maintains | Buy | $159 → $170 |
| 25 Aug 2026 | Needham | Maintains | Buy | — |
| 11 Aug 2026 | UBS | Maintains | Neutral | $145 → $158 |
| 11 Aug 2026 | UBS | Maintains | Neutral | — |
| 10 Aug 2026 | Truist Securities | Maintains | Hold | — |
| 10 Aug 2026 | Truist Securities | Maintains | Hold | $143 → $150 |
| 7 Aug 2026 | Piper Sandler | Reiterates | Overweight | — |
| 7 Aug 2026 | Piper Sandler | Reiterates | Overweight | $160 → $169 |
| 31 July 2026 | Needham | Maintains | Buy | $147 → $159 |
| 31 July 2026 | Needham | Maintains | Buy | — |
| 28 July 2026 | UBS | Initiates | Neutral | $145 |
| 28 July 2026 | UBS | Initiates | Neutral | — |
| 15 July 2026 | Mizuho | Maintains | Neutral | $140 → $145 |
| 15 July 2026 | Mizuho | Maintains | Neutral | — |
| 9 July 2026 | BMO Capital | Initiates | Outperform | $159 |
| 9 July 2026 | BMO Capital | Initiates | Outperform | — |
| 8 June 2026 | Piper Sandler | Upgrade | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TFX appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Teleflex, Inc. returned +6.0% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 44% of US stocks
Cheaper than 43% of US stocks
Cheaper than 14% of US stocks
Higher than 77% of US stocks
Higher than 21% of US stocks
Higher than 71% of US stocks
Higher than 64% of US stocks
Higher than 11% of US stocks
Higher than 43% of US stocks
Higher than 57% of US stocks
Higher than 70% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Teleflex, Inc. has a market value of $5.8B and an enterprise value of $8.4B.
Revenue in the twelve months to 30 June 2026: $1.6B. The latest quarter grew 28.9% year on year.
Net income over the same four quarters: −$1.0B, a −63.3% net margin.
Diluted earnings per share, trailing twelve months: $−23.29.
Free cash flow in the twelve months to 30 June 2026: $327.1M, after $76.1M of capital spending.
Teleflex, Inc. spent $250.0M on share buybacks and $59.9M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 2735.6×; forward P/E: 12.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.00%, paying out 104% of earnings.
Teleflex, Inc. employs 15,500 people — $105K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Teleflex, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Teleflex announced that the FDA granted Breakthrough Device Designation to its Freesolve Resorbable Magnesium Scaffold for percutaneous coronary intervention.
Why it matters — The designation is a regulatory development for a Teleflex device intended for PCI that may address an unmet clinical need.
Teleflex will host a conference call at 8:00 a.m. Eastern Time on November 5, 2026, to discuss third-quarter financial results and provide an operational update. Participants can pre-register for dial-in details or access the live audio webcast through the company website.
Why it matters — The call will provide TFX watchers with information about the company’s third-quarter results and operations.
Teleflex announced that patient enrollment is complete in the BIOMAG™-LL Clinical Study, which evaluates the safety and clinical performance of its Freesolve™ Resorbable Magnesium Scaffold in 35 mm and 40 mm lengths for treating de novo coronary lesions up to 38 mm.
Why it matters — The enrollment milestone advances a clinical study examining longer scaffold lengths and adds to the clinical evidence Teleflex is developing for the product.
Zacks Investment Research compares Teleflex and SONOVA HOLDING for investors interested in medical-instruments stocks, asking which offers better value.
Why it matters — The item frames TFX in a value-stock comparison with SONOVA HOLDING, which may interest investors assessing Teleflex's relative value.
Zacks Investment Research weighs Teleflex's Vascular growth, expansion in Asia and improved leverage against risks from tariffs, input costs and margin pressure.
Why it matters — These supporting factors and risks are relevant to TFX watchers assessing the company's outlook.
The 12 Wall Street analysts covering Teleflex, Inc. have a median 12-month price target of $155, with estimates ranging from $138 to $170. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Teleflex, Inc., 6 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Teleflex, Inc. 77 out of 100 across roughly 4,600 US stocks as at 26 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 26 Oct 2026, Teleflex, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +11.5% from the last close, and Ticker Nerd's factor model ranks Teleflex, Inc. 77 out of 100 as at 26 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Teleflex, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TFX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $138 to $170 over the next 12 months.
Teleflex, Inc. returned +6.0% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Teleflex Incorporated is a global medical technology company that designs, develops, manufactures, and supplies single-use devices used in critical care, surgery, and other hospital procedures. Teleflex Incorporated’s portfolio spans vascular access, anesthesia, emergency medicine, interventional cardiology and radiology, surgical applications, respiratory care, and urology, serving hospitals, healthcare providers, and medical device partners.
The most recent item we track (Business Wire, 22 Oct 2026): "Teleflex Announces FDA Breakthrough Device Designation for Freesolve™ Resorbable Magnesium Scaffold". Teleflex announced that the FDA granted Breakthrough Device Designation to its Freesolve Resorbable Magnesium Scaffold for percutaneous coronary intervention.
Teleflex Incorporated is a global medical technology company that designs, develops, manufactures, and supplies single-use devices used in critical care, surgery, and other hospital procedures. Teleflex Incorporated’s portfolio spans vascular access, anesthesia, emergency medicine, interventional cardiology and radiology, surgical applications, respiratory care, and urology, serving hospitals, healthcare providers, and medical device partners. The company also provides original equipment manufacturing services, supporting other medical device makers with components and specialized products. Its offerings are used in diagnostic and therapeutic procedures that require reliable, procedure-focused tools across a broad range of clinical settings. Headquartered in Wayne, Pennsylvania and founded in 1943, Teleflex Incorporated operates as a diversified healthcare equipment provider with a strong presence across the Americas, EMEA, and Asia.
CEO Mr. Jason Weidman · 15,500 employees · United States · https://www.teleflex.com
